Authors : Damilola Egbewole; Deborah Oluwatobi Alabi; Ellen Wakisa Nyasulu Chiwoni; Chioma Okerulu

Volume/Issue : Volume 10 - 2025, Issue 8 - August

Google Scholar : https://tinyurl.com/mppn9vta

Scribd : https://tinyurl.com/ybzczzxc

DOI : https://doi.org/10.38124/ijisrt/25aug746

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : This cross-sectional study compared inflammatory and metabolic biomarkers in four patient groups—HIV infection, acute COVID-19, type 2 diabetes mellitus (T2DM), and polycystic ovary syndrome (PCOS)—attending Baze University Teaching Hospital, Abuja, Nigeria, between January and June 2025. A total of 200 adults (50 per group) were assessed for high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), fasting glucose, fasting insulin, and homeostatic model assessment of insulin resistance (HOMA-IR). HIV and COVID-19 cohorts exhibited significantly higher hs-CRP (mean ± SD: 6.7 ± 2.4 mg/L and 8.3 ± 3.1 mg/L, respectively) and IL-6 (45.3 ± 15.2 pg/mL and 55.8 ± 18.4 pg/mL, respectively) compared with T2DM and PCOS (p < 0.001). In contrast, T2DM and PCOS groups had higher HOMA-IR values (4.5 ± 1.5 and 3.9 ± 1.4, respectively) than HIV and COVID-19 (p < 0.001). Moderate positive correlations were observed between IL-6 and HOMA-IR (r = 0.52, p < 0.001) and between hs-CRP and fasting glucose (r = 0.45, p < 0.001). These results indicate that while inflammatory activation predominates in HIV and COVID-19, metabolic dysregulation is more pronounced in T2DM and PCOS. The findings underscore the value of combined inflammatory-metabolic biomarker panels in guiding early detection, risk stratification, and integrated management of non-communicable and infectious disease comorbidities in Nigerian clinical practice.

Keywords : Inflammatory Biomarkers, Metabolic Biomarkers, HIV, COVID-19, Polycystic Ovary Syndrome (PCOS).

References :

1. Del Valle, D. M., Kim-Schulze, S., Huang, H. H., et al. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature Medicine, 26(10), 1636–1643. https://doi.org/10.1038/s41591-020-1051-9
2. Huang, C., Wang, Y., Li, X., et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
3. Liu, F., Li, L., Xu, M., et al. (2020). Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. Journal of Clinical Virology, 127, 104370. https://doi.org/10.1016/j.jcv.2020.104370
4. Kuller, L. H., Tracy, R., Belloso, W., et al. (2008). Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Medicine, 5(10), e203. https://doi.org/10.1371/journal.pmed.0050203
5. Borges, Á. H., O’Connor, J. L., Phillips, A. N., et al. (2014). Interleukin 6 is a stronger predictor of clinical events than high-sensitivity C-reactive protein or D-dimer during HIV infection. The Journal of Infectious Diseases, 210(4), 609–618. https://doi.org/10.1093/infdis/jiu158
6. Hunt, P. W., Sinclair, E., Rodriguez, B., et al. (2011). Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. The Journal of Infectious Diseases, 203(11), 1634–1641. https://doi.org/10.1093/infdis/jir324
7. Shoelson, S. E., Lee, J., & Goldfine, A. B. (2006). Inflammation and insulin resistance. The Journal of Clinical Investigation, 116(7), 1793–1801. https://doi.org/10.1172/JCI29069
8. Effoe, V., Huang, Y., & Thakar, D. (2021). Inflammation and metabolic dysregulation: Interactions in diabetes and cardiovascular risk. Current Diabetes Reports, 21(9), 36. https://doi.org/10.1007/s11892-021-01374-8
9. Ezenwaka, C. E., Offiah, N. V., Nwaogwugwu, N. C., & Uche, N. (2014). Insulin resistance in apparently healthy Nigerian adults: relationship with waist circumference and body mass index. Nigerian Journal of Clinical Practice, 17(2), 169–173. https://doi.org/10.4103/1119-3077.127553
10. Azziz, R., Carmina, E., Chen, Z., et al. (2016). Polycystic ovary syndrome. Nature Reviews Disease Primers, 2, 16057. https://doi.org/10.1038/nrdp.2016.57
11. González, F., Rote, N. S., Minium, J., & Kirwan, J. P. (2006). Increased activation of nuclear factor kappa B triggers inflammation and insulin resistance in polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 91(4), 1508–1512. https://doi.org/10.1210/jc.2005-2327
12. Escobar-Morreale, H. F., Luque-Ramírez, M., & González, F. (2010). Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and meta-analysis. Fertility and Sterility, 94(3), 1058–1065. https://doi.org/10.1016/j.fertnstert.2009.06.033
13. Rocha, M. P., Marcondes, J. A., Barcellos, C. R., et al. (2015). Metabolic syndrome in women with polycystic ovary syndrome: prevalence and associated factors. Revista Brasileira de Ginecologia e Obstetrícia, 37(8), 362–368. https://doi.org/10.1590/S0100-720320150005471
14. Pradhan, A. D., Manson, J. E., Rifai, N., Buring, J. E., & Ridker, P. M. (2001). C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 286(3), 327–334. https://doi.org/10.1001/jama.286.3.327
15. Hotamisligil, G. S. (2017). Inflammation, metaflammation and immunometabolic disorders. Nature, 542(7640), 177–185. https://doi.org/10.1038/nature21363
16. Pickup, J. C. (2004). Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care, 27(3), 813–823. https://doi.org/10.2337/diacare.27.3.813
17. Brown, T. T., Li, X., Cole, S. R., et al. (2005). Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Archives of Internal Medicine, 165(10), 1179–1184. https://doi.org/10.1001/archinte.165.10.1179
18. Nou, E., Lo, J., & Grinspoon, S. K. (2016). Inflammation, immune activation, and cardiovascular disease in HIV. AIDS, 30(10), 1495–1509. https://doi.org/10.1097/QAD.0000000000001109
19. Zhou, F., Yu, T., Du, R., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet, 395(10229), 1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3
20. World Health Organization. (2022). Noncommunicable diseases: Country profiles 2022. Geneva: WHO. Available at: https://www.who.int/publications/i/item/9789240064926
21. Fernández-Real, J. M., & Pickup, J. C. (2008). Innate immunity, insulin resistance and type 2 diabetes. Trends in Endocrinology & Metabolism, 19(1), 10–16. https://doi.org/10.1016/j.tem.2007.10.004
22. Reaven, G. M. (2011). Insulin resistance: the link between obesity and cardiovascular disease. Medical Clinics of North America, 95(5), 875–892. https://doi.org/10.1016/j.mcna.2011.06.002